

# Martina Brueckmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7762537/publications.pdf>

Version: 2024-02-01

54  
papers

9,976  
citations

136885

32  
h-index

168321

53  
g-index

54  
all docs

54  
docs citations

54  
times ranked

6836  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
2	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
3	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet</i> , 2020, 396, 819-829.	6.3	816
4	Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2019, 380, 1906-1917.	13.9	568
5	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	15.2	341
6	Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis. <i>Circulation</i> , 2005, 112, 527-534.	1.6	284
7	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
8	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
9	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	2.9	205
10	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
11	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	2.9	155
12	Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus). <i>International Journal of Stroke</i> , 2015, 10, 1309-1312.	2.9	147
13	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	1.0	144
14	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
15	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
16	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
17	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	1.0	114
18	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106

#	ARTICLE	IF	CITATIONS
19	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	1.2	105
20	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	1.0	96
21	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	1.2	94
22	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
23	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	2.9	60
24	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1204-1209.	0.7	54
25	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	1.2	52
26	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 682-690.	2.4	47
27	Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. <i>Thrombosis and Haemostasis</i> , 2005, 93, 743-750.	1.8	43
28	Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. <i>Cytokine</i> , 2004, 26, 106-113.	1.4	41
29	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	1.0	39
30	Markers of Myocardial Damage, Tissue Healing, and Inflammation After Radiofrequency Catheter Ablation of Atrial Tachyarrhythmias. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 686-691.	0.8	38
31	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	1.0	38
32	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. <i>PLoS ONE</i> , 2014, 9, e99276.	1.1	33
33	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	1.0	33
34	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. <i>Circulation</i> , 2021, 144, 1738-1746.	1.6	31
35	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1529-1538.	2.9	30
36	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	0.8	29

#	ARTICLE	IF	CITATIONS
37	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	5.5	29
38	Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1132-9.	1.4	26
39	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	1.2	21
40	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
41	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2393-2398.	2.9	19
42	Efficacy and Cost-Effectiveness of Dabigatran Etxilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups. <i>American Journal of Cardiology</i> , 2014, 114, 849-855.	0.7	17
43	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	0.8	14
44	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
45	Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C. <i>Thrombosis and Haemostasis</i> , 2003, 89, 149-60.	1.8	11
46	Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting. <i>Thrombosis Journal</i> , 2016, 14, 8.	0.9	10
47	Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells. <i>British Journal of Haematology</i> , 2006, 133, 550-557.	1.2	9
48	Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure. <i>Thrombosis Research</i> , 2003, 109, 259-263.	0.8	7
49	N-terminal pro-atrial natriuretic peptide as a biochemical marker of long-term interventional success after radiofrequency catheter ablation of paroxysmal supraventricular tachyarrhythmias. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 896-902.	1.4	5
50	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , 2019, 21, 1023-1030.	0.7	5
51	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	1.6	5
52	Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5
53	Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. <i>Thrombosis Research</i> , 2016, 143, 103-110.	0.8	4
54	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". <i>Circulation</i> , 2014, 130, e95.	1.6	0